| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5583893 | Seminars in Arthritis and Rheumatism | 2017 | 15 Pages |
Abstract
All available TNF-inhibitors showed similar treatment responses with or without csDMARDs. Adalimumab was associated with better drug survival when compared to infliximab.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Kalle PhD, Arto BSc, Jaana MSc, Pinja MD, Anna MD, PhD, Tuire MD, Toini MD, PhD, Maija MD, Leena MD, Marja PhD, Tuulikki MD, PhD, Dan MD, PhD,